NDV-HXP-S
Sign in to saveAlso known as ButanVac, CoviVac, Patria
In the Vinony graph
Vinony's link graph records 1,285 inbound references to NDV-HXP-S, and connects out to SARS-CoV-2, Pfizer–BioNTech COVID-19 vaccine and Gam-COVID-Vac.
It is catalogued under topics including American COVID-19 vaccines, Chemical articles without CAS registry number and Chemical pages without ChemSpiderID.
Vinony links it to 8 Wikipedia language editions.
Wikidata facts
- Subclass of
- viral vector vaccine
- Image
- Coletiva de imprensa para anúncio da Butanvac a vacina 100% nacional (51072730543).jpg
Show 1 more fact
- Commons category
- ButanVac
Sources (1)
via Wikidata · CC0
~3 min read
Encyclopedic overview
6 sectionsContents
- Pharmacology
- Manufacturing
- History
- Development
- Clinical trials
- References
NDV-HXP-S (known as ButanVac or ADAPTCOV in Brazil, COVIVAC in Vietnam, HXP-GPOVac in Thailand, Patria in Mexico) is a COVID-19 vaccine candidate developed under the leadership of Peter Palese, Adolfo García-Sastre, and Florian Krammer at the Icahn School of Medicine at Mount Sinai, in New York, United States.
The name NDV-HXP-S comes from the terms Newcastle disease virus, HexaPro, and spike protein. The stabilization of the S protein of SARS-CoV-2 (HexaPro) was achieved by Jason McLellan from the University of Texas at Austin.
Excerpted from Wikipedia’s “NDV-HXP-S” article, available under the CC BY-SA 4.0 licence.